Key Points
- Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals on June 5 at an average price of $53.14, totaling about $63,236.60. After the sale, she still owned 1,455 shares, reducing her stake by 44.99%.
- Xenon Pharmaceuticals recently reported quarterly earnings of -$1.17 per share, matching Wall Street expectations. Analysts now expect the company to post -4.92 EPS for the current fiscal year.
- Analysts remain broadly bullish on XENE, with a consensus rating of “Buy” and an average price target of $77.20. Recent targets range from $60 to $97, reflecting continued optimism despite the company’s loss profile.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) Director Gillian Cannon sold 1,190 shares of the company's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Xenon Pharmaceuticals Stock Performance
XENE opened at $51.21 on Tuesday. Xenon Pharmaceuticals Inc. has a one year low of $30.00 and a one year high of $63.95. The stock has a market capitalization of $4.95 billion, a PE ratio of -10.90 and a beta of 0.62. The business's 50 day moving average price is $55.74 and its 200 day moving average price is $48.68.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting analysts' consensus estimates of ($1.17). During the same period last year, the firm earned ($0.83) earnings per share. As a group, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.
Institutional Trading of Xenon Pharmaceuticals
Large investors have recently modified their holdings of the stock. Neo Ivy Capital Management purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $2,001,000. JPMorgan Chase & Co. increased its position in shares of Xenon Pharmaceuticals by 11.3% during the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company's stock worth $56,171,000 after acquiring an additional 142,452 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $5,342,000. HighVista Strategies LLC increased its position in shares of Xenon Pharmaceuticals by 80.2% during the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company's stock worth $3,300,000 after acquiring an additional 36,570 shares during the period. Finally, Peregrine Capital Management LLC purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $7,837,000. Hedge funds and other institutional investors own 95.45% of the company's stock.
Analyst Ratings Changes
XENE has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an "outperform" rating in a report on Friday, May 8th. Wolfe Research started coverage on Xenon Pharmaceuticals in a research note on Monday, February 23rd. They set an "outperform" rating and a $60.00 price target on the stock. Wells Fargo & Company restated an "overweight" rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $77.20.
Read Our Latest Analysis on XENE
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
